Virtu Financial LLC raised its stake in Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) by 66.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,384 shares of the company’s stock after purchasing an additional 8,970 shares during the period. Virtu Financial LLC owned 0.11% of Zynerba Pharmaceuticals worth $121,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new position in Zynerba Pharmaceuticals in the third quarter valued at approximately $177,000. Jane Street Group LLC grew its position in shares of Zynerba Pharmaceuticals by 44.6% during the third quarter. Jane Street Group LLC now owns 35,555 shares of the company’s stock worth $290,000 after acquiring an additional 10,967 shares during the last quarter. Two Sigma Investments LP purchased a new position in shares of Zynerba Pharmaceuticals during the fourth quarter worth approximately $120,000. Campbell Capital Management Inc. purchased a new position in shares of Zynerba Pharmaceuticals during the fourth quarter worth approximately $510,000. Finally, Deutsche Bank AG grew its position in shares of Zynerba Pharmaceuticals by 17,314.3% during the fourth quarter. Deutsche Bank AG now owns 279,500 shares of the company’s stock worth $830,000 after acquiring an additional 277,895 shares during the last quarter. Institutional investors own 12.95% of the company’s stock.
NASDAQ:ZYNE opened at $12.52 on Wednesday. Zynerba Pharmaceuticals Inc has a 1-year low of $2.75 and a 1-year high of $12.89. The firm has a market capitalization of $231.56 million, a P/E ratio of -4.80 and a beta of 4.93.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings data on Monday, March 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.21. The firm had revenue of $0.09 million during the quarter. As a group, equities analysts anticipate that Zynerba Pharmaceuticals Inc will post -2.1 earnings per share for the current year.
A number of brokerages have recently issued reports on ZYNE. ValuEngine upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday. Roth Capital assumed coverage on shares of Zynerba Pharmaceuticals in a research report on Tuesday. They set a “buy” rating and a $36.00 target price on the stock. Canaccord Genuity assumed coverage on shares of Zynerba Pharmaceuticals in a research report on Monday, April 22nd. They issued a “buy” rating and a $8.09 price objective on the stock. Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research report on Friday, March 22nd. Finally, HC Wainwright reiterated a “buy” rating on shares of Zynerba Pharmaceuticals in a research report on Monday, March 18th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Zynerba Pharmaceuticals has a consensus rating of “Buy” and an average price target of $17.02.
Zynerba Pharmaceuticals Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder.
Recommended Story: Preferred Stock
Receive News & Ratings for Zynerba Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.